STOCK TITAN
  1. Home
  2. Sec-filings
  3. MLTX
  4. [Form 4] MoonLake Immunotherapeutics Insider Trading Activity

MoonLake (MLTX) CFO sells 17,876 shares in pre-set 10b5-1 plan

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt reported open-market sales of 17,876 Class A ordinary shares. The shares were sold on two days at weighted average prices of about $19.60 and $19.68 per share under a Rule 10b5-1 trading plan adopted on December 10, 2025. Following these transactions, he continues to hold 1,154,555 shares directly.

Positive

  • None.

Negative

  • None.
Insider Bodenstedt Matthias
Role Chief Financial Officer
Sold 17,876 shs ($352K)
Type Security Shares Price Value
Sale Class A ordinary shares, par value $0.0001 per share 2,794 $19.60 $55K
Sale Class A ordinary shares, par value $0.0001 per share 15,082 $19.68 $297K
Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 1,154,555 shares (Direct, null)
Footnotes (1)
  1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.505 to $19.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Total shares sold 17,876 shares Net shares sold across two open-market transactions
Shares sold on June 18, 2026 2,794 shares Open-market sale at weighted average price $19.60
Shares sold on June 17, 2026 15,082 shares Open-market sale at weighted average price $19.68
Remaining holdings 1,154,555 shares Class A ordinary shares held directly after transactions
Price range for $19.60 average $19.50–$20.06 Range of individual trade prices for one sale batch
Price range for $19.68 average $19.505–$19.70 Range of individual trade prices for second sale batch
10b5-1 plan adoption date December 10, 2025 Date CFO adopted pre-arranged Rule 10b5-1 trading plan
Class A ordinary shares financial
"Class A ordinary shares, par value $0.0001 per share"
Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported represents the weighted average sale price per share."
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bodenstedt Matthias
(Last)(First)(Middle)
C/O MOONLAKE IMMUNOTHERAPEUTICS
DORFSTRASSE 29
(Street)
ZUG6300
(City)(State)(Zip)
SWITZERLAND
(Country)		2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A ordinary shares, par value $0.0001 per share06/17/2026S(1)15,082D$19.68(2)1,157,349D
Class A ordinary shares, par value $0.0001 per share06/18/2026S(1)2,794D$19.6(3)1,154,555D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.505 to $19.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
/s/ Matthias Bodenstedt06/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MoonLake Immunotherapeutics (MLTX) disclose?

MoonLake Immunotherapeutics reported that CFO Matthias Bodenstedt sold 17,876 Class A ordinary shares in the open market. The trades occurred on two dates in June at weighted average prices near $19.60 and $19.68 per share under a trading plan.

At what prices did the MoonLake (MLTX) CFO sell his shares?

The CFO’s reported weighted average sale prices were $19.60 and $19.68 per share. Footnotes note the shares were sold in multiple transactions within ranges from $19.50 to $20.06 and from $19.505 to $19.70.

How many MoonLake (MLTX) shares does the CFO hold after these sales?

After the reported open-market sales, CFO Matthias Bodenstedt directly holds 1,154,555 Class A ordinary shares. This figure is disclosed as the total number of shares beneficially owned following the most recent transaction date in the Form 4 filing.

Were the MoonLake (MLTX) CFO share sales under a Rule 10b5-1 plan?

Yes, the filing states the transactions were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025. Such pre-arranged plans allow insiders to sell shares on a preset schedule, reducing discretion over trade timing.

How many MoonLake (MLTX) shares did the CFO sell on each date?

The CFO sold 2,794 shares on June 18, 2026 at a weighted average price of $19.60, and 15,082 shares on June 17, 2026 at a weighted average price of $19.68, according to the Form 4 transaction table.

What trading ranges did the MoonLake (MLTX) CFO’s share sales cover?

Footnotes explain the sales at $19.60 averaged across trades from $19.50 to $20.06. The $19.68 average reflects trades between $19.505 and $19.70. The CFO will provide detailed breakdowns upon appropriate request.